TNX-102 SL is a non-opioid, centrally-acting analgesic administered at bedtime for the treatment of fibromyalgia. The Food ...

TNX-102 SL is a non-opioid, centrally-acting analgesic administered at bedtime for the treatment of fibromyalgia. The Food and Drug Administration (FDA) has accepted the New Drug Application (NDA ...

a non-opioid, centrally acting analgesic designed for fibromyalgia management. The FDA is expected to assign a Prescription Drug User Fee Act (PDUFA) target action date in its Day 74 Letter ...

giving fibromyalgia sufferers a much-needed new non-opioid option. As it stands, Tonix believes 85% of fibromyalgia patients fail their first-line therapy, and 79% are on multiple therapies.

Tonix Pharmaceuticals Holding said the Food and Drug Administration has accepted its application seeking approval of its TNX-102 SL product candidate for the chronic pain condition fibromyalgia.